Evolution of hepatitis B virus polymerase mutations in a patient with HBeAg-positive chronic hepatitis B virus treated with sequential monotherapy and add-on nucleoside/nucleotide analogues

Clinical Therapeutics

Volumn 31, Issue 2, 2009, Pages 360-366

  Wang, Feifei ^a,b   Wang, Honghai ^b   Shen, Hongbo ^b   Meng, Chengyan ^a   Weng, Xinhua ^a   Zhang, Wenhong ^a,b  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

drug resistance; hepatitis B virus; mutations; nucleoside nucleotide analogues

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; BILIRUBIN; CREATININE; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; MEMBRANE ANTIGEN; NUCLEOSIDE DERIVATIVE; RNA DIRECTED DNA POLYMERASE; TELBIVUDINE;

ADD ON THERAPY; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC RESISTANCE; ARTICLE; BILIRUBIN BLOOD LEVEL; BIOCHEMISTRY; BLOOD CELL COUNT; BLOOD SAMPLING; CASE REPORT; CHINESE; CHRONIC HEPATITIS; CREATININE BLOOD LEVEL; DNA EXTRACTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; GENETIC TRANSCRIPTION; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; MICROPARTICLE ENZYME IMMUNOASSAY; MOLECULAR CLONING; MOLECULAR EVOLUTION; MONOTHERAPY; PATIENT COMPLIANCE; REAL TIME POLYMERASE CHAIN REACTION; VIRUS MUTATION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; CHRONIC DISEASE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; RNA-DIRECTED DNA POLYMERASE; YOUNG ADULT;

EID: 62149121677     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.02.016     Document Type: Article

References (32)

1. Lee W.M. Hepatitis B virus infection. N Engl J Med 337 (1997) 1733-1745
2. Conjeevaram H.S., and AS L. Management of chronic hepatitis B [published correction appears in J Hepatol. 2003;38:876]. J Hepatol 38 Suppl 1 (2003) S90-S103
3. Bruix J., and Llovet J.M. Hepatitis B virus and hepatocellular carcinoma. J Hepatol 39 Suppl 1 (2003) S59-S63
4. Marcellin P., Chang T.T., Lim S.G., et al., for the Adefovir Dipivoxil 437 Study Group. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 348 (2003) 808-816
5. Lai C.L., Rosmawati M., Lao J., et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 123 (2002) 1831-1838
6. Lai C.L. Therapeutic advances in chronic hepatitis B. J Gastroenterol Hepatol 19 Suppl (2004) S5-S9
7. Locarnini S., Hatzakis A., Heathcote J., et al. Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther 9 (2004) 679-693
8. Zoulim F. Antiviral therapy of chronic hepatitis B. Antiviral Res 71 (2006) 206-215
9. Zoulim F. Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. Antiviral Res 64 (2004) 1-15
10. Liu C.J., Chen P.J., Lai M.Y., et al. Hepatitis B virus variants in patients receiving lamivudine treatment with breakthrough hepatitis evaluated by serial viral loads and full-length viral sequences. Hepatology 34 (2001) 583-589
11. Fung S.K., Andreone P., Han S.H., et al. Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol 43 (2005) 937-943
12. Wang J.H., Lu S.N., Lee C.M., et al. Fatal hepatic failure after emergence of the hepatitis B virus mutant during lamivudine therapy in a patient with liver cirrhosis. Scand J Gastroenterol 37 (2002) 366-369
13. Chen C.H., Lee C.M., Lu S.N., et al. Comparison of clinical outcome between patients continuing and discontinuing lamivudine therapy after biochemical breakthrough of YMDD mutants. J Hepatol 41 (2004) 454-461
14. Lai C.L., Chien R.N., Leung N.W., et al., for the Asia Hepatitis Lamivudine Study Group. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 339 (1998) 61-68
15. Lai C.L., Dienstag J., Schiff E., et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 36 (2003) 687-696
16. Yatsuji H., Hiraga N., Mori N., et al. Successful treatment of an entecavirresistant hepatitis B virus variant. J Med Virol 79 (2007) 1811-1817
17. Allen M.I., Deslauriers M., Andrews C.W., et al., for the Lamivudine Clinical Investigation Group. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 27 (1998) 1670-1677
18. Rapti I., Dimou E., Mitsoula P., and Hadziyannis S.J. Adding-on versus switching to adefovir therapy in lamivudine-resistant HBeAg negative chronic hepatitis B. Hepatology 45 (2007) 307-313
19. Angus P., Vaughan R., Xiong S., et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 125 (2003) 292-297
20. Villeneuve J.P., Durantel D., Durantel S., et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol 39 (2003) 1085-1089
21. Chang T.T., and Lai C.L. Hepatitis B virus with primary resistance to adefovir. N Engl J Med. 355 (2006) 322-323 author reply 323
22. Schildgen O., Sirma H., Funk A., et al. Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med 354 (2006) 1807-1812
23. Amarapurkar D.N. Telbivudine: A new treatment for chronic hepatitis B. World J Gastroenterol 13 (2007) 6150-6155
24. Tyzeka (telbivudine) tablets [prescribing information] (October 2006), Idenix Pharmaceuticals, Inc and Novartis Pharmaceuticals Corporation, Cambridge, Mass and East Hanover, NJ
25. Lai C.L., Leung N., Teo E.K., et al., for the Telbivudine Phase II Investigator Group. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 129 (2005) 528-536
26. Férir G., Kaptein S., Neyts J., and De Clercq E. Antiviral treatment of chronic hepatitis B virus infections: The past, the present and the future. Rev Med Virol 18 (2008) 19-34
27. Yeh C.T., Chien R.N., Chu C.M., and Liaw Y.F. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology 31 (2000) 1318-1326
28. Dai C.Y., Chuang W.L., Hsieh M.Y., et al. Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B. Antiviral Res 75 (2007) 146-151
29. Buti M., Elefsiniotis I., Jardi R., et al. Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients. J Hepatol 47 (2007) 366-372
30. Yim H.J., Hussain M., Liu Y., et al. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 44 (2006) 703-712
31. Villet S., Pichoud C., Villeneuve J.P., et al. Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology 131 (2006) 1253-1261
32. Moriconi F., Colombatto P., Coco B., et al. Emergence of hepatitis B virus quasispecies with lower susceptibility to nucleos(t)ide analogues during lamivudine treatment. J Antimicrob Chemother 60 (2007) 341-349